While tobacco and alcohol are known to increase the risk of head and neck cancer, new research has found the amount of coffee ...

PAX-1 is under clinical development by Komipharm International and currently in Phase I for Head And Neck Cancer.

CTX-471 is under clinical development by Compass Therapeutics and currently in Phase I for Head And Neck Cancer.

The Jimmy Carter drug introduced the world to cancer immunotherapy, a treatment that differs from chemotherapy. Carter was ...

The biotherapeutics company said the treatment, LYT-200, is being evaluated in two ongoing clinical trials. It was previously granted orphan drug designation for the treatment of acute myeloid ...

GORTEC, known as Head and Neck Radiation Oncology Group, today announced that the randomized Phase 3 NIVOPOSTOP GORTEC ...

Rahway, NJ, USA) anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in first line recurrent/metastatic head ... this novel IO combination in head and neck squamous cell cancers with PD-L1 CPS <1.

Obsessed with chai Or Coffee Well its your day to be happy Recent research suggests that this daily ritual might be lowering ...

(Alliance News) - PureTech Health PLC on Thursday said that the US Food & Drug Administration has granted fast track designation to its antibody LYT-200 for the treatment of acute myeloid leukemia.

LYT-200 is currently being evaluated in two Phase 1/2 trials for the potential treatment of AML/MDS and head and neck cancers PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company” ...